Filing Details

Accession Number:
0001567619-20-017382
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-10-01 21:01:34
Reporting Period:
2020-09-29
Accepted Time:
2020-10-01 21:01:34
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1787306 Arcutis Biotherapeutics Inc. ARQT () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1252999 W David Osborne C/O Arcutis Biotherapeutics, Inc.
2945 Townsgate Road, Suite 110
Westlake Village CA 91361
Chief Technical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2020-09-29 15,000 $30.00 264,279 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 62,478 Indirect By Trust
Common Stock 62,478 Indirect By Trust
Footnotes
  1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
  2. Includes 9,000 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof.
  3. The securities are held of record by The Osborne Irrevocable Trust FBO John Osborne, of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
  4. The securities are held of record by The Osborne Irrevocable Trust FBO Sharon Osborne, of which the Reporting Person is trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.